Neuropharmacology and potential efficacy of new treatments for tobacco dependence
- 24 January 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (2) , 107-116
- https://doi.org/10.1517/13543784.15.2.107
Abstract
(2006). Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs: Vol. 15, No. 2, pp. 107-116. doi: 10.1517/13543784.15.2.107Keywords
This publication has 51 references indexed in Scilit:
- CB1 receptor antagonists for the treatment of nicotine addictionPharmacology Biochemistry and Behavior, 2005
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleusNicotine & Tobacco Research, 2004
- Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like EffectsNeuropsychopharmacology, 2004
- Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and SensitizationScience, 2004
- SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking CessationThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking BehaviorNeuropsychopharmacology, 2003
- Nicotine dependence: Studies with a laboratory modelPharmacology Biochemistry and Behavior, 2001
- Role of nicotine dose and sensory cues in the regulation of smoke intakePharmacology Biochemistry and Behavior, 1993
- Rodent model of nicotine abstinence syndromePharmacology Biochemistry and Behavior, 1992